/

Società

Ac

Non verificato

Accord Healthcare

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaSanitàStart-up

8 comunicati stampa

Guarda tutti i comunicati

02/04/2025

Farmaceutica

Sanità

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®

Fonte

Accord Healthcare

Emittente

1.00

0

06/02/2025

Farmaceutica

Sanità

Biologia

Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)

Fonte

Accord Healthcare

Emittente

1.00

0

Press Release cover image

31/01/2025

Farmaceutica

Sanità

Economia

Start-up

Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a supportive agent in the treatment of alcoholism

Fonte

Accord Healthcare

Emittente

1.00

0

Press Release cover image

16/12/2024

Farmaceutica

Sanità

Biologia

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

Fonte

Accord Healthcare

Emittente

1.00

0

01/11/2024

Farmaceutica

Sanità

Imprese

Organizzazione Aziendale

Accord Healthcare unlocks £50m government fund to boost medicines manufacturing in the North-East

Fonte

Accord Healthcare

Emittente

1.00

0

19/10/2024

Farmaceutica

Sanità

Biologia

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Fonte

Accord Healthcare

Emittente

1.00

0

21/09/2024

Farmaceutica

Sanità

Economia

Start-up

Biologia

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

Fonte

Accord Healthcare

Emittente

1.00

0

14/08/2024

Farmaceutica

Sanità

Economia

Start-up

NICE recommends ORGOVYX® (relugolix) as the first oral ADT treatment for hormone sensitive prostate cancer in England

Fonte

Accord Healthcare

Emittente

1.00

0

Seguaci

0

Compatibilità

0